Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-a (IFN) Refractoriness/Intolerance.

被引：0
|
作者：
Kantarjian, Hagop M.
Sawyers, Charles
Hochhaus, Andreas
Schiffer, Charles A.
Guilhot, Francois
Niederwieser, Dietger W.
Gambacorti, Carlo
Stone, Richard M.
Fischer, Thomas
Goldman, John
Krahnke, T.
Mone, M.
Talpaz, Moshe
Druker, Brian J.
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Karmanos Canc Inst, Detroit, MI USA
[5] CHU La Miletrie, Poitiers, France
[6] Univ Leipzig, D-7010 Leipzig, Germany
[7] Inst Natl Tumori, Milan, Italy
[8] Dana Farber Canc Inst, Boston, MA USA
[9] Univ Mainz, D-6500 Mainz, Germany
[10] NHLBI, Bethesda, MD 20892 USA
[11] Univ Michigan, Ann Arbor, MI 48109 USA
[12] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
428
引用
收藏
页码：130A / 131A
页数：2
相关论文
共 50 条
  • [41] Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).
    Maiti, Abhishek
    Kantarjian, Hagop M.
    Patel, Keyur
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Kadia, Tapan M.
    Skinner, Jeffrey A.
    Poku, Rebecca A.
    Dellasala, Sara
    Luthra, Rajyalakshmi
    Jabbour, Elias
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP
    Clark, R.
    Reiffers, J.
    Kim, D. W.
    Rosti, G.
    Kurokawa, M.
    Moiraghi, B.
    Larson, R.
    Saglio, G.
    Hughes, T.
    Woodman, R.
    Blakesley, R.
    Kemp, C.
    Kantarjian, H.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 237 - 237
  • [43] ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
    Hughes, T. P.
    le Coutre, P. D.
    Jootar, S.
    Reiffers, J.
    Turkina, A. G.
    Saglio, G.
    Hochhaus, A.
    Kantarjian, H. M.
    Kemp, C.
    Deng, W.
    Menssen, H. D.
    Larson, R. A.
    HAEMATOLOGICA, 2014, 99 : 236 - 237
  • [44] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u)
    Kantarjian, Hagop
    Flinn, Ian W.
    Goldberg, Stuart
    Bunworasate, Udomsak
    Zanichelli, Maria Aparecida
    Nakamae, Hirohisa
    Hughes, Timothy P.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Woodman, Richard Charles
    Blakesley, Rick E.
    Kemp, Charisse N.
    Kalaycio, Matt E.
    Larson, Richard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Homoharringtonine (HHT) for chronic myeloid leukemia in accelerated phase (CML AP): A follow-up study.
    Al-Beirouti, BM
    Chen, C
    Yee, K
    Kamel-Reid, S
    Keating, A
    BLOOD, 2001, 98 (11) : 254B - 255B
  • [46] Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
    Pepe, Sara
    Scalzulli, Emilia
    Colafigli, Gioia
    Di Prima, Alessio
    Mancini, Marco
    Diverio, Daniela
    Latagliata, Roberto
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2261 - 2266
  • [47] Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib
    Breccia, Massimo
    Loglisci, Giuseppina
    Salaroli, Adriano
    Serrao, Alessandra
    Zacheo, Irene
    Latagliata, Roberto
    Alimena, Giuliana
    BLOOD, 2012, 120 (21)
  • [48] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
    Talpaz, M.
    Cortes, J. E.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D. L.
    Flinn, I. W.
    O'Hare, T. J.
    Hu, S.
    Rivera, V. M.
    Clackson, T.
    Conlan, M. G.
    Haluska, F. G.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2015, 100 : 65 - 66
  • [49] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Bixby, Dale L.
    Flinn, Ian
    O'Hare, Thomas J.
    Hu, Simin
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W. N.
    Mauro, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).
    Gambacorti-Passerini, Carlo
    Abboud, Camille N.
    Gjertsen, Bjorn T.
    Brummendorf, Tim H.
    Smith, B. Douglas
    Giraldo-Castellano, Pilar
    Olsson-Stromberg, Ulla
    Saussele, Susanne
    Bardy-Bouxin, Nathalie
    Viqueira, Andrea
    Leip, Eric
    Leone, Jocelyn M.
    Rosti, Gianantonio
    Watts, Justin M.
    Giles, Frank
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345